erythropoietin

Also found in: Thesaurus, Medical, Acronyms, Encyclopedia, Wikipedia.

e·ryth·ro·poi·e·tin

(ĭ-rĭth′rō-poi-ē′tĭn)

1. A glycoprotein hormone that stimulates the production of red blood cells by stem cells in bone marrow. Produced mainly by the kidneys, it is released in response to decreased levels of oxygen in body tissue.

2. Epoetin alfa.

[erythropoiet(ic) + -in.]

American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.

erythropoietin

(ɪˌrɪθrəʊpɔɪˈiːtɪn)

(Biochemistry) a hormone, secreted by the kidney in response to low levels of oxygen in the tissues, that increases the rate of erythropoiesis. It has been used as a performance-enhancing drug for athletes and racehorses. Abbreviation: EPO

Collins English Dictionary – Complete and Unabridged, 12th Edition 2014 © HarperCollins Publishers 1991, 1994, 1998, 2000, 2003, 2006, 2007, 2009, 2011, 2014

e•ryth•ro•poi•e•tin

(ɪˌrɪθ roʊˈpɔɪ ɪ tn, -pɔɪˈit n)

n.

a hormone that stimulates production of red blood cells and hemoglobin in the bone marrow.

[1945–50]

ThesaurusAntonymsRelated WordsSynonymsLegend:

Switch to new thesaurus

Noun

erythropoietin - a glycoprotein secreted by the kidneys that stimulates the production of red blood cells

glycoprotein - a conjugated protein having a carbohydrate component

Translations

EpoetinErythropoetinErythropoietinHämatopoetin

eritropoietina

e·ryth·ro·poi·e·tin

[MIM*133170]

n. eritropoyetina, proteína no dializable que estimula la producción de eritrocitos.

English-Spanish Medical Dictionary © Farlex 2012

erythropoietin

n eritropoyetina

Mentioned in ?

References in periodicals archive ?

Kidneys produce hormones including erythropoietin, which stimulates red blood cell production.

Kyowa Kirin Announces Daprodustat Submission in Japan by GSK for Patients with Anemia due to Chronic Kidney Disease

Additionally, Competitive Analysis By Erythropoietin Drug Market Players, Opportunities, Future Roadmap, And Major Vendor Profiles Has Been Presented In The Report.

Erythropoietin Drug Market Opportunity Analysis and Industry Forecast 2019 Business Opportunity, Global Trend, Future Growth, Key Findings and Forecast To 2023

[USPRwire, Wed Jul 31 2019] Erythropoietin is a hormone which produce inside the body from kidney.

Erythropoietin Drugs Market Size, Share, Trends and Future Growth Predictions and Forecast 2017 -- 20

[ClickPress, Wed Jul 31 2019] Erythropoietin is a hormone which produce inside the body from kidney.

Erythropoietin Drugs Market Size, Share, Trends and Future Growth Predictions and Forecast 2017 -- 20

Recombinant erythropoietin in urine-an artificial hormone taken to boost athletic performance can now be detected.

Detecting the neurogenesis effect of erythropoietin and galantamine in the dentate gyrus and spatial memory in Alzheimer's experimental rat model

Erythropoietin induces a shift of muscle phenotype from fast glycolytic to slow oxidative.

INFLUENCIA DA ERITROPOETINA HUMANA RECOMBINANTE SOBRE CONCENTRACOES DE LACTATO EM ANIMAIS TREINADOS

The exclusion criteria were pregnancy, treatment with erythropoietin products, hematologic condition, malignant diseases, and failure to obtain consent for participation in the study.

ERYTHROPOIETIN IN THE EVALUATION OF TREATMENT OUTCOMES IN PATIENTS WITH POLYTRAUMA

Recombinant human erythropoietin increased the expression of CD34 and vascular endothelial growth factor receptor 2 through phosphatidylinositol 3 kinase/Akt pathway

Recombinant Human Erythropoietin Augments Neovascularization Responses in a Neonatal Rat Model of Premature Brain Damage by Phosphatidylinositol 3 Kinase/Akt Pathway

An overall cost analysis will be studied with respect to hemodiafitration versus hemodialysis treatment, nursing training time, and possibly, over time, a decrease in usage of erythropoietin stimulating agent and phosphate binding agents.

Is hemodiafiltration the ultimate fix?

The polycythaemias are usually classified as relative and absolute.1 Relative polycythaemia is a condition in which the patient characteristically has an elevation of the hematocrit level without an elevated red cell mass but it is due to contraction of the plasma volume, in contrast the absolute polycythaemias are accompanied by an actual increase in the red cell mass.1 Polycythaemias can also be classified according to the response of their erythroid progenitor cells to growth factors like erythropoietin or the circulating levels of it.1,2 Primary polycythaemias are characterized by increased sensitivity of the erythroid progenitors to regulatory growth factors, as a result of acquired somatic or inherited mutations expressed by progenitor cells.

FREQUENCY AND CLINICOMORPHOLOGICAL FEATURES OF JAK2V617F POSITIVE AND NEGATIVE POLYCYTHEMIA IN A TERTIARY CARE HOSPITAL OF PAKISTAN

- The global erythropoietin drugs market is projected to grow to USD 10.39bn by 2021, according to a new report from UK-based technology research and advisory company.

Global Erythropoietin Drugs Market to Reach USD 10.39bn by 2021, Technavio Forecasts

Daprodustat will be evaluated in the two studies whether it is non-inferior or not to recombinant human erythropoietin on the endpoints considered as the primary analysis.